© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
Chicago-Patients with carcinoma in situ or recurrent Ta, Tis, or T1 bladdercancer are at increased risk of dying of the disease within 5 years unlessthey achieve a complete response with bacille Calmette-Guérin therapy,say researchers from the Southwest Oncology Group.